Cytotoxicity and growth-inhibiting activity of Astragalus polysaccharides against breast cancer via the regulation of EGFR and ANXA1

Astragalus polysaccharide (APS) has been frequently used as an adjuvant agent responsible for its immunoregulatory activity to enhance efficacy and reduce toxicity of chemotherapy used in the management of breast cancer. However, the other synergism mechanism of APS remains unclear. This study was p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of natural medicines 2021-09, Vol.75 (4), p.854-870
Main Authors: Li, Wenfang, Hu, Xueyan, Li, Yanjie, Song, Kedong
Format: Article
Language:English
Subjects:
Antitumor agents
Apoptosis
Biological products
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cell cycle
Cell death
Cell proliferation
Chemotherapy
Complementary & Alternative Medicine
Cytotoxicity
Epidermal growth factor receptors
Gene expression
Immunoregulation
Insulin-like growth factor I
Medicinal Chemistry
Original Paper
Pharmacology/Toxicology
Pharmacy
Plant Sciences
Polysaccharides
Proteins
Tumor cell lines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Astragalus polysaccharide (APS) has been frequently used as an adjuvant agent responsible for its immunoregulatory activity to enhance efficacy and reduce toxicity of chemotherapy used in the management of breast cancer. However, the other synergism mechanism of APS remains unclear. This study was performed to evaluate the potential targets and possible mechanism behind APS in vivo direct anti-tumor activity on breast cancer. Multiple biological detections were conducted to investigate the protein and mRNA expression levels of key targets. In total, 116 down-regulated and 73 up-regulated differential expressed genes (DEGs) were examined from 7 gene expression datasets. Top ten hub genes were obtained in four typical protein–protein interaction (PPI) network of DEGs involved in each specific biological process (BP, cell cycle, cell proliferation, cell apoptosis and death) that was related to inhibitory activity of APS in vitro against breast cancer cell lines. Four common DEGs (EGFR, ANXA1, KIF14 and IGF1) were further identified in the above four BP-PPI networks, among which EGFR and ANXA1 were the hub genes that were potentially linked to the progression of breast cancer. The results of biological detections indicated that the expression of EGFR in breast cancer cells was down-regulated, while the expression of ANXA1 was markedly increased in response to APS. In conclusion, the present study may provide potential molecular therapeutic targets and a new insight into the mechanism of APS against breast cancer. Graphic abstract
ISSN:1340-3443
1861-0293
DOI:10.1007/s11418-021-01525-x